CGN Nuclear Technology Development Co (000881) Fair Value & Analysis
Industrials · CN · Market cap 6.7B CNY
Analysis
CGN Nuclear Technology Development Co (000881) currently trades at ¥6.79, while our model-based Fair Value estimate is ¥1.64 — implying the stock looks roughly 75.8% overvalued today. We read business quality at 85/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
CGN Nuclear Technology Development Co., Ltd. manufactures and sells cable materials and industrial electron accelerators in China. It provides ground nanoaccelerators, electronic curtain accelerators, DG resonant transformer accelerators, and industrial flaw detection accelerators. The company is also involved in the provision of electron beam treatment of specialty waste; antibiotic residue treatment technology; pharmaceutical wastewater treatment technology; medical sewage and solid waste disposal; park sewage treatment; printing and dyeing wastewater treatment technology; coal chemical coking wastewater treatment technology; chemical wastewater treatment technology; domestic sewage treatment technology; and hazardous waste concentrate treatment services. In addition, it provides new energy, irradiated, elastomer, and synthetic materials; modified polycarbonate and polyester, modified polypropylene, continuous fiber reinforced thermoplastic composites, and melt blown and radiation…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.